{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "REGULAR", "exchange": "NYQ", "shortName": "Bristol-Myers Squibb Company", "longName": "Bristol-Myers Squibb Company", "messageBoardId": "finmb_25798", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.4962544, "regularMarketPrice": 67.15, "firstTradeDateMilliseconds": 76253400000, "tradeable": false, "cryptoTradeable": false, "regularMarketDayHigh": 68.1, "regularMarketDayRange": "66.93 - 68.1", "regularMarketDayLow": 66.93, "regularMarketVolume": 4984333, "regularMarketPreviousClose": 68.17, "bid": 67.13, "ask": 67.14, "bidSize": 10, "askSize": 10, "fullExchangeName": "NYSE", "financialCurrency": "USD", "regularMarketOpen": 68.06, "averageDailyVolume3Month": 7757276, "averageDailyVolume10Day": 8555350, "fiftyTwoWeekLowChange": 1.8700027, "fiftyTwoWeekLowChangePercent": 0.028645877, "fiftyTwoWeekRange": "65.28 - 81.44", "fiftyTwoWeekHighChange": -14.290001, "fiftyTwoWeekHighChangePercent": -0.17546661, "fiftyTwoWeekLow": 65.28, "fiftyTwoWeekHigh": 81.44, "dividendDate": 1682899200, "earningsTimestamp": 1690459200, "earningsTimestampStart": 1690459200, "earningsTimestampEnd": 1690459200, "trailingAnnualDividendRate": 2.22, "trailingPE": 19.57726, "priceHint": 2, "regularMarketChange": -1.0199966, "regularMarketTime": 1684262585, "trailingAnnualDividendYield": 0.032565646, "epsTrailingTwelveMonths": 3.43, "epsForward": 8.15, "epsCurrentYear": 8.05, "priceEpsCurrentYear": 8.341615, "sharesOutstanding": 2100850048, "bookValue": 15.154, "fiftyDayAverage": 68.4324, "fiftyDayAverageChange": -1.282402, "fiftyDayAverageChangePercent": -0.018739691, "twoHundredDayAverage": 72.1144, "twoHundredDayAverageChange": -4.9644012, "twoHundredDayAverageChangePercent": -0.06884064, "marketCap": 141072089088, "forwardPE": 8.2392645, "priceToBook": 4.4311733, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "symbol": "BMY"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "430 East 29th Street", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10016", "country": "United States", "phone": "212 546 4000", "website": "https://www.bms.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.", "fullTimeEmployees": 34300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Giovanni  Caforio M.D.", "age": 57, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 5763527, "fmt": "5.76M", "longFmt": "5,763,527"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David V. Elkins", "age": 54, "title": "Exec. VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2724676, "fmt": "2.72M", "longFmt": "2,724,676"}, "exercisedValue": {"raw": 2826282, "fmt": "2.83M", "longFmt": "2,826,282"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christopher S. Boerner Ph.D.", "age": 51, "title": "Exec. VP, COO & Director", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 2624023, "fmt": "2.62M", "longFmt": "2,624,023"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sandra  Leung Esq.", "age": 61, "title": "Exec. VP & Gen. Counsel", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 2663774, "fmt": "2.66M", "longFmt": "2,663,774"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Rupert  Vessey BCH, BM, DPHIL, M.A.", "age": 57, "title": "Exec. VP & Pres of Research", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 2755979, "fmt": "2.76M", "longFmt": "2,755,979"}, "exercisedValue": {"raw": 1662641, "fmt": "1.66M", "longFmt": "1,662,641"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Greg  Meyers", "age": 49, "title": "Exec. VP and Chief Digital & Technology Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy  Power", "title": "VP & Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cari  Gallman", "title": "Sr. VP & Chief Compliance and Ethics Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ann M. Powell Judge", "age": 56, "title": "Exec. VP & Chief HR Officer", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Fouad  Namouni M.D.", "age": 53, "title": "Head of Oncology Devel.", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 1, "shareHolderRightsRisk": 3, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}